ARCH Venture Fund X Overage, L.P. — SEC insider filings

SEC reporting owner CIK 1757017. 14 insider filings on record with FilingPulse; latest filed 2026-11-02.

Transaction summary — filings shown

Covers all 14 filings on record, filed 2021-02-10 to 2026-11-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Prime Medicine, Inc. (PRME)10% owner34 legs · 7,030,300 sh · $43,599,990—6
Neumora Therapeutics, Inc. (NMRA)10% owner32 legs · 3,415,700 sh · $30,499,977—12
Aspen Neuroscience, Inc. (ASPE)10% owner23 legs · 1,333,333 sh · $19,999,995—18
Sana Biotechnology, Inc. (SANA)10% owner23 legs · 1,818,181 sh · $9,999,996—14
Boundless Bio, Inc. (BOLD)10% owner22 legs · 200,000 sh · $3,200,0001 leg · 16,000 sh · $39,84012
Erasca, Inc. (ERAS)10% owner1——8
Verve Therapeutics, Inc. (VERV)10% owner1——6

Insider filings — ARCH Venture Fund X Overage, L.P.

FiledFormIssuerReported transactionsSource
2026-11-024Aspen Neuroscience, Inc. (ASPE)
jointly with ARCH Venture Fund X, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, Burow Kristina, GILLIS STEVEN, NELSEN ROBERT
Purchase (P): 66,666 @ $15 · Conversion (C): 187,182 · Conversion (C): 298,258 · Conversion (C): 286,304 · Conversion (C): 295,490 · Conversion (C): 259,948 · +15 moreEDGAR
2026-10-293Aspen Neuroscience, Inc. (ASPE)
jointly with ARCH Venture Fund X, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, Burow Kristina, GILLIS STEVEN, NELSEN ROBERT
Holdings only — no transactions reportedEDGAR
2026-07-064Boundless Bio, Inc. (BOLD)
jointly with ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners IX, LLC, ARCH Venture Partners X, LLC
Option exercise (M): 16,000 @ $1.03 · Sale (S): 16,000 @ $2.49 · Option exercise (M): 16,000 (derivative) @ $0EDGAR
2025-10-294Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners VII, LLC, ARCH Venture Partners VII, L.P., ARCH Venture Fund VII, L.P., ARCH Venture Partners VIII, LLC, ARCH Venture Fund VIII Overage, L.P.
Purchase (P): 1,915,700 @ $2.61EDGAR
2025-08-014Prime Medicine, Inc. (PRME)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN
Purchase (P): 3,030,300 @ $3.30EDGAR
2024-04-044Boundless Bio, Inc. (BOLD)
jointly with ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners IX, LLC, ARCH Venture Partners X, LLC
Conversion (C): 589,743 · Conversion (C): 787,545 · Conversion (C): 1,048,433 · Purchase (P): 66,667 @ $16 · Purchase (P): 133,333 @ $16 · Conversion (C): 424,908 (derivative) · +6 moreEDGAR
2024-02-204Prime Medicine, Inc. (PRME)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN
Purchase (P): 3,200,000 @ $6.25EDGAR
2024-02-124Sana Biotechnology, Inc. (SANA)
jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners IX, LLC, ARCH Venture Partners X, LLC
Purchase (P): 363,637 @ $5.50 · Purchase (P): 727,272 @ $5.50 · Purchase (P): 727,272 @ $5.50EDGAR
2023-12-124Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners VII, LLC, ARCH Venture Partners VII, L.P., ARCH Venture Fund VII, L.P., ARCH Venture Partners VIII, LLC, ARCH Venture Fund VIII Overage, L.P.
Other (J): 703,061 · Other (J): 1,176,593EDGAR
2023-09-204Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners VII, LLC, ARCH Venture Partners VII, L.P., ARCH Venture Fund VII, L.P., ARCH Venture Partners VIII, LLC, ARCH Venture Fund VIII Overage, L.P.
Conversion (C): 684,167 · Conversion (C): 1,144,973 · Conversion (C): 6,895,021 · Conversion (C): 6,576,400 · Conversion (C): 2,124,143 · Purchase (P): 1,500,000 @ $17 · +5 moreEDGAR
2022-10-264Prime Medicine, Inc. (PRME)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN
Conversion (C): 5,728,297 · Conversion (C): 5,728,297 · Purchase (P): 400,000 @ $17 · Purchase (P): 400,000 @ $17 · Conversion (C): 16,666,667 (derivative) @ $0 · Conversion (C): 16,666,664 (derivative) @ $0 · +2 moreEDGAR
2021-07-204Erasca, Inc. (ERAS)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., NELSEN ROBERT, CRANDELL KEITH, Burow Kristina, GILLIS STEVEN
Conversion (C): 5,527,777 · Conversion (C): 5,527,777 · Conversion (C): 2,100,000 (derivative) · Conversion (C): 2,100,000 (derivative) · Conversion (C): 3,400,000 (derivative) · Conversion (C): 1,133,333 (derivative) · +2 moreEDGAR
2021-06-234Verve Therapeutics, Inc. (VERV)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., CRANDELL KEITH, NELSEN ROBERT, Burow Kristina, GILLIS STEVEN
Conversion (C): 1,254,404 · Conversion (C): 1,254,405 · Conversion (C): 7,107,024 (derivative) · Conversion (C): 7,107,023 (derivative) · Conversion (C): 4,508,144 (derivative) · Conversion (C): 4,508,146 (derivative)EDGAR
2021-02-104Sana Biotechnology, Inc. (SANA)
jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners IX, LLC, ARCH Venture Partners X, LLC
Conversion (C): 10,156,250 · Conversion (C): 10,156,250 · Conversion (C): 11,718,750 · Conversion (C): 11,718,750 · Conversion (C): 3,687,500 (derivative) @ $0 · Conversion (C): 3,687,500 (derivative) @ $0 · +8 moreEDGAR

FilingPulse's Form 4 archive currently extends back to 2021-02-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1757017 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs